Agios Pharmaceuticals Inc

Of the nine analysts covering Agios Pharmaceuticals (AGIO) in March 2018, one gave it a “strong buy” rating, and six gave it a “buy” rating.

Fourteen analysts were tracking Bioverativ in January 2018. Four analysts recommended “strong buys,” while two recommended “buys” on the stock.

In December 2017, Jazz Pharmaceuticals (JAZZ) submitted a New Drug Application (or NDA) to the FDA for the approval of JZP-110.

In July 2017, Jazz Pharmaceuticals entered into a license agreement with XL-Protein GmbH involving products using XL-Protein’s PASylation technology.

In early 2017, Jazz Pharmaceuticals (JAZZ) expanded its sales force team from 35 to 55 and expanded its field reimbursement teams to support the commercial launch of Vyxeos in the US.

If Vyxeos manages to penetrate a sizeable portion of the target market, it may have a favorable impact on Jazz Pharmaceuticals stock.

Of the 27 analysts covering Celgene (CELG) in August 2017, 12 analysts recommended a “strong buy,” and ten analysts recommended a “buy.”

In December 2016, Celgene’s and Juno Therapeutics’ (JUNO) novel investigational drug, JCAR017, was given breakthrough designation by the US Food and Drug Administration (or FDA).

Three analysts recommended a “buy” for Agios (AGIO), eight analysts recommended a “hold,” and no analysts recommended a “sell” for the stock. Agios has a weight of 2.2% in XBI’s portfolio.

Agios Pharmaceuticals (AGIO) stock rose 14% after it announced the initiation of the Phase 1b trial of either AG-221 or AG-120.

Biotech stocks and ETFs had a good day on December 21 and rose marginally. The iShares Nasdaq Biotechnology ETF (IBB) rose 0.2% for the day and closed at $332.13.